Home > Newsletters > Drug Industry Daily > Good Communication Can Minimize Study Disruptions During IRB Transfers: Draft Guidance
Drug Industry Daily
June 14, 2012 | Vol. 11 No. 117
Good Communication Can Minimize Study Disruptions During IRB Transfers: Draft Guidance
To smoothly transition clinical investigation oversight from one institutional review board (IRB) to another, drugmakers, contract research organizations (CRO), new and old IRBs and clinical investigators should work closely to minimize disruptions to the ongoing trial and ensure subjects are constantly protected, according to a new draft guidance.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.